Format

Send to

Choose Destination
J Control Release. 2012 Apr 10;159(1):2-13. doi: 10.1016/j.jconrel.2011.10.023. Epub 2011 Oct 26.

Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Author information

1
Intramural Research Program, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Peptides are attracting increasing attention as therapeutic agents, as the technologies for peptide development and manufacture continue to mature. Concurrently, with booming research in nanotechnology for biomedical applications, peptides have been studied as an important class of components in nanomedicine, and they have been used either alone or in combination with nanomaterials of every reported composition. Peptides possess many advantages, such as smallness, ease of synthesis and modification, and good biocompatibility. Their functions in cancer nanomedicine, discussed in this review, include serving as drug carriers, as targeting ligands, and as protease-responsive substrates for drug delivery.

PMID:
22056916
PMCID:
PMC3288222
DOI:
10.1016/j.jconrel.2011.10.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center